Dr. Heikki Joensuu

Home/Tag: Dr. Heikki Joensuu

New Tool Available for Calculating GIST Recurrence

updated 6/22/20 The GIST Risk Calculator is based on research from Dr. Heikki Joensuu, Professor of Oncology at the University of Helsinki and the Research Director at the Helsinki Comprehensive Cancer Center, and his colleagues. The [...]

By |2020-06-22T09:17:59-04:00September 15th, 2016|News, Risk Assessment|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Update on Potential Treatments for Imatinib-Resistant GIST

In a recent article entitled "Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions" published online in Springer for Research and Development,  LRG Research Team member Sebastian Bauer [...]

By |2019-10-31T12:01:30-04:00July 31st, 2015|News, Research|

New Study Reviews Follow-Up Treatment Strategies for GIST

In a recent article in the May 2015 edition of the European Journal of Cancer, Heikki Joensuu, one of the foremost authorities on adjuvant treatment for GIST, discussed how follow-up treatment is currently performed for [...]

By |2018-11-05T15:34:20-05:00June 30th, 2015|News, Research, Survival Strategies|

LRG & colleagues make their mark on 17th annual CTOS meeting in Prague

Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.

By |2019-09-20T13:18:16-04:00February 1st, 2013|Events, News|
Go to Top